Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures (2021 - 2025)

Kiniksa Pharmaceuticals International's Capital Expenditures history spans 5 years, with the latest figure at -$852000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 1221.05% year-over-year to -$852000.0; the TTM value through Dec 2025 reached $83000.0, down 70.04%, while the annual FY2025 figure was $83000.0, 70.04% down from the prior year.
  • Capital Expenditures reached -$852000.0 in Q4 2025 per KNSA's latest filing, down from $671000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $671000.0 in Q3 2025 to a low of -$852000.0 in Q4 2025.
  • Average Capital Expenditures over 5 years is $45500.0, with a median of $52500.0 recorded in 2021.
  • The largest YoY upside for Capital Expenditures was 1016.67% in 2025 against a maximum downside of 1221.05% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $251000.0 in 2021, then plummeted by 112.75% to -$32000.0 in 2022, then soared by 37.5% to -$20000.0 in 2023, then soared by 480.0% to $76000.0 in 2024, then tumbled by 1221.05% to -$852000.0 in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Capital Expenditures are -$852000.0 (Q4 2025), $671000.0 (Q3 2025), and $165000.0 (Q2 2025).